



TransEnterix Schedules Second Quarter Financial and Operating Results Conference Call for August 5, 2020

July 22, 2020

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Jul. 22, 2020-- TransEnterix, Inc. (NYSE American: TRXC) announced today that it plans to release second quarter financial and operating results after the market closes on Wednesday, August 5, 2020. The Company will host a conference call to discuss these results starting at 4:30 p.m. Eastern Time the same day. The call will be concurrently webcast.

To listen to the conference call on your telephone, please dial 1-855-327-6837 for domestic callers and 1-631-891-4304 for international callers, and reference conference ID 10010432 approximately ten minutes prior to the start time. To access the live audio webcast or archived recording, use the following link <http://ir.transenterix.com/events.cfm>. The replay will be available on the Company's website.

About TransEnterix

TransEnterix is a medical device company that is digitizing the interface between the surgeon and the patient to improve minimally invasive surgery by addressing the clinical and economic challenges associated with current laparoscopic and robotic options in today's value-based healthcare environment. The Company is focused on the market development activities for, and increasing utilization of, its Senhance Surgical System, which digitizes laparoscopic minimally invasive surgery. The system allows for robotic precision, haptic feedback, surgeon camera control via eye sensing and improved ergonomics while offering responsible economics. The Senhance Surgical System is available for sale in the US, the EU, Japan and select other countries. For more information, visit www.transenterix.com.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20200722005126/en/): <https://www.businesswire.com/news/home/20200722005126/en/>

TransEnterix, Inc.

Investors:

Mark Klausner, 443-213-0501

invest@transenterix.com

or

Media:

Terri Clevenger, 203-856-8297

terri.clevenger@icrinc.com

Source: TransEnterix, Inc.